MDWD - MediWound's burn treatment Nexobrid approved in Japan
- MediWound ( NASDAQ: MDWD ) said on Friday its Japanese partner Kaken Pharma had gained marketing approval of burn treatment, NexoBrid, in Japan.
- Kaken has the exclusive right to market and distribute NexoBrid in Japan and expects to launch it in the summer of 2023.
- The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted NexoBrid marketing authorization for non-surgical eschar removal of deep-partial and full-thickness thermal burns for the adult and pediatric patients.
- Japan is the first country in the world to approve NexoBrid for people of all ages.
For further details see:
MediWound's burn treatment Nexobrid approved in Japan